Drugs / miRisten
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07025564 | Oct 2025 → Mar 2028 | acute myeloid leukemia | City of Hope Medical Center | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | miRisten | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07025564 ↗ |
| Action | Inhibit | “miR-126 inhibitor miRisten” NCT07025564 ↗ |
| Modality | Antisense oligonucleotide | “CpG-linked Anti-Mir-126 Oligonucleotide” NCT07025564 ↗ |
| Route | Intravenous | “Given IV” NCT07025564 ↗ |